A Two-Cohort, Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 [ticagrelor]in Healthy Chinese Volunteers Living in China
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Ticagrelor (Primary)
- Indications Cardiovascular disorders; Embolism and thrombosis
- Focus Pharmacokinetics
- 21 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2008 New trial record.